Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evalua...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Rose, Peter G., Java, James J., Morgan, Mark A., Secord, Angeles Alvarez, Kesterson, Joshua P., Stehman, Frederick B., Warshal, David P., Creasman, William T., Hanjani, Parviz, Morris, Robert T., Copeland, Larry J.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720165/
https://ncbi.nlm.nih.gov/pubmed/27692669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.09.005
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items